Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease.
Pedro-Botet J, López-Miranda J, Badimón L, Civeira F, Guijarro C, Millán J, Mostaza JM, Pintó X, Valdivielso P, Masana L; Expert group from the Spanish Arteriosclerosis Society. Pedro-Botet J, et al. Among authors: pinto x. Am J Cardiovasc Drugs. 2020 Aug;20(4):325-332. doi: 10.1007/s40256-019-00376-y. Am J Cardiovasc Drugs. 2020. PMID: 31650523 Review.
Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.
Gómez-Gerique JA, Ros E, Oliván J, Mostaza JM, Vilardell M, Pintó X, Civeira F, Hernández A, da Silva PM, Rodriguez-Botaro A, Zambón D, Lima J, Díaz C, Aristegui R, Sol JM, Chaves J, Hernández G; ATOMIX Investigators. Gómez-Gerique JA, et al. Among authors: pinto x. Atherosclerosis. 2002 Jun;162(2):245-51. doi: 10.1016/s0021-9150(01)00708-0. Atherosclerosis. 2002. PMID: 11996943 Clinical Trial.
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Ascaso JF, Fernández-Cruz A, González Santos P, Hernández Mijares A, Mangas Rojas A, Millán J, Felipe Pallardo L, Pedro-Botet J, Pérez-Jiménez F, Pía G, Pintó X, Plaza I, Rubiés-Prat J; HDL Forum. Ascaso JF, et al. Among authors: pinto x. Am J Cardiovasc Drugs. 2004;4(5):299-314. doi: 10.2165/00129784-200404050-00003. Am J Cardiovasc Drugs. 2004. PMID: 15449972 Review.
Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
Lahoz C, Peña R, Mostaza JM, Laguna F, García-Iglesias MF, Taboada M, Pintó X. Lahoz C, et al. Among authors: pinto x. Metabolism. 2005 Jun;54(6):741-7. doi: 10.1016/j.metabol.2004.12.020. Metabolism. 2005. PMID: 15931608 Clinical Trial.
429 results